Bromocriptine	B:C0006230
Induces	O
Autophagy	O
-	O
Dependent	O
Cell	O
Death	I:C0007587
in	O
Pituitary	O
Adenomas	I:C0032000
.	O

Bromocriptine	O
Induces	O
Autophagy	B:C0004391
-	O
Dependent	O
Cell	O
Death	I:C0007587
in	O
Pituitary	O
Adenomas	I:C0032000
.	O

Bromocriptine	O
Induces	O
Autophagy	O
-	O
Dependent	O
Cell	B:C0007587
Death	I:C0007587
in	O
Pituitary	O
Adenomas	I:C0032000
.	O

Bromocriptine	O
Induces	O
Autophagy	O
-	O
Dependent	O
Cell	O
Death	I:C0007587
in	O
Pituitary	B:C0032000
Adenomas	I:C0032000
.	O

Bromocriptine	B:C0006230
(	O
Bromocriptine	O
)	O
is	O
effective	O
in	O
patients	O
with	O
prolactinoma	O
.	O

Bromocriptine	O
(	O
Bromocriptine	B:C0006230
)	O
is	O
effective	O
in	O
patients	O
with	O
prolactinoma	O
.	O

Bromocriptine	O
(	O
Bromocriptine	O
)	O
is	O
effective	O
in	O
patients	O
with	O
prolactinoma	B:C0033375
.	O

However	O
,	O
the	O
cytotoxic	O
mechanism	O
of	O
Bromocriptine	B:C0006230
remains	O
unknown	O
.	O

Slices	O
for	O
immunohistochemical	O
pathology	B:C0030664
were	O
randomly	O
selected	O
from	O
37	O
paraffin	O
-	I:C1519524
embedded	I:C1519524
prolactinoma	I:C1519524
tissue	I:C1519524
sections	O
.	O

Slices	O
for	O
immunohistochemical	O
pathology	O
were	O
randomly	O
selected	O
from	O
37	O
paraffin	B:C1519524
-	I:C1519524
embedded	I:C1519524
prolactinoma	I:C1519524
tissue	I:C1519524
sections	O
.	O

LC3	B:C2003747
was	O
detected	O
by	O
immunohistochemistry	O
.	O

LC3	O
was	O
detected	B:C0442726
by	O
immunohistochemistry	O
.	O

LC3	O
was	O
detected	O
by	O
immunohistochemistry	B:C0021044
.	O

GH3	B:C0229535
and	O
MMQ	O
cells	I:C0229535
were	O
treated	O
by	O
Bromocriptine	O
and	O
/	O
or	O
rapamycin	O
(	O
rapamycin	O
)	O
.	O

GH3	O
and	O
MMQ	B:C0229535
cells	I:C0229535
were	O
treated	O
by	O
Bromocriptine	O
and	O
/	O
or	O
rapamycin	O
(	O
rapamycin	O
)	O
.	O

GH3	O
and	O
MMQ	O
cells	I:C0229535
were	O
treated	O
by	O
Bromocriptine	B:C0006230
and	O
/	O
or	O
rapamycin	O
(	O
rapamycin	O
)	O
.	O

GH3	O
and	O
MMQ	O
cells	I:C0229535
were	O
treated	O
by	O
Bromocriptine	O
and	O
/	O
or	O
rapamycin	B:C0072980
(	O
rapamycin	O
)	O
.	O

GH3	O
and	O
MMQ	O
cells	I:C0229535
were	O
treated	O
by	O
Bromocriptine	O
and	O
/	O
or	O
rapamycin	O
(	O
rapamycin	B:C0072980
)	O
.	O

Cell	B:C0007620
viability	I:C0007620
and	O
the	O
cell	O
cycle	I:C0007586
were	O
measured	O
by	O
CCK	O
-	I:C2986858
8	I:C2986858
and	O
flow	O
cytometry	I:C0016263
,	O
respectively	O
.	O

Cell	O
viability	I:C0007620
and	O
the	O
cell	B:C0007586
cycle	I:C0007586
were	O
measured	O
by	O
CCK	O
-	I:C2986858
8	I:C2986858
and	O
flow	O
cytometry	I:C0016263
,	O
respectively	O
.	O

Cell	O
viability	I:C0007620
and	O
the	O
cell	O
cycle	I:C0007586
were	O
measured	O
by	O
CCK	B:C2986858
-	I:C2986858
8	I:C2986858
and	O
flow	O
cytometry	I:C0016263
,	O
respectively	O
.	O

Cell	O
viability	I:C0007620
and	O
the	O
cell	O
cycle	I:C0007586
were	O
measured	O
by	O
CCK	O
-	I:C2986858
8	I:C2986858
and	O
flow	B:C0016263
cytometry	I:C0016263
,	O
respectively	O
.	O

Enzyme	B:C0014441
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
measured	O
prolactin	O
secretion	I:C2611224
.	O

Enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
measured	O
prolactin	B:C2611224
secretion	I:C2611224
.	O

Protein	B:C1171362
expression	I:C1171362
was	O
detected	O
by	O
Western	O
blot	I:C0005863
or	O
immunofluorescence	O
.	O

Protein	O
expression	I:C1171362
was	O
detected	B:C0442726
by	O
Western	O
blot	I:C0005863
or	O
immunofluorescence	O
.	O

Protein	O
expression	I:C1171362
was	O
detected	O
by	O
Western	B:C0005863
blot	I:C0005863
or	O
immunofluorescence	O
.	O

Protein	O
expression	I:C1171362
was	O
detected	O
by	O
Western	O
blot	I:C0005863
or	O
immunofluorescence	B:C0079603
.	O

LC3	B:C2003747
was	O
significantly	O
expressed	O
in	O
prolactinoma	O
in	O
which	O
patients	O
were	O
treated	O
exclusively	O
with	O
Bromocriptine	O
.	O

LC3	O
was	O
significantly	O
expressed	B:C1171362
in	O
prolactinoma	O
in	O
which	O
patients	O
were	O
treated	O
exclusively	O
with	O
Bromocriptine	O
.	O

LC3	O
was	O
significantly	O
expressed	O
in	O
prolactinoma	B:C0033375
in	O
which	O
patients	O
were	O
treated	O
exclusively	O
with	O
Bromocriptine	O
.	O

LC3	O
was	O
significantly	O
expressed	O
in	O
prolactinoma	O
in	O
which	O
patients	O
were	O
treated	O
exclusively	O
with	O
Bromocriptine	B:C0006230
.	O

LC3	B:C1171362
expression	I:C1171362
was	O
negative	O
in	O
normal	O
tissues	O
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	O
with	I:C0332293
Bromocriptine	O
.	O

LC3	O
expression	I:C1171362
was	O
negative	B:C0205160
in	O
normal	O
tissues	O
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	O
with	I:C0332293
Bromocriptine	O
.	O

LC3	O
expression	I:C1171362
was	O
negative	O
in	O
normal	O
tissues	B:C0040300
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	O
with	I:C0332293
Bromocriptine	O
.	O

LC3	O
expression	I:C1171362
was	O
negative	O
in	O
normal	O
tissues	O
and	O
prolactinoma	B:C0033375
in	O
which	O
patients	O
were	O
not	O
treated	O
with	I:C0332293
Bromocriptine	O
.	O

LC3	O
expression	I:C1171362
was	O
negative	O
in	O
normal	O
tissues	O
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	B:C0332293
with	I:C0332293
Bromocriptine	O
.	O

LC3	O
expression	I:C1171362
was	O
negative	O
in	O
normal	O
tissues	O
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	O
with	I:C0332293
Bromocriptine	B:C0006230
.	O

Treatment	B:C0087111
with	O
60	O
μM	O
Bromocriptine	O
for	O
24	O
hours	O
induced	O
cell	O
death	I:C0007587
in	O
MMQ	O
cells	I:C0229535
by	O
up	O
to	O
50	O
%	O
.	O

Treatment	O
with	O
60	O
μM	O
Bromocriptine	B:C0006230
for	O
24	O
hours	O
induced	O
cell	O
death	I:C0007587
in	O
MMQ	O
cells	I:C0229535
by	O
up	O
to	O
50	O
%	O
.	O

Treatment	O
with	O
60	O
μM	O
Bromocriptine	O
for	O
24	O
hours	O
induced	O
cell	B:C0007587
death	I:C0007587
in	O
MMQ	O
cells	I:C0229535
by	O
up	O
to	O
50	O
%	O
.	O

Treatment	O
with	O
60	O
μM	O
Bromocriptine	O
for	O
24	O
hours	O
induced	O
cell	O
death	I:C0007587
in	O
MMQ	B:C0229535
cells	I:C0229535
by	O
up	O
to	O
50	O
%	O
.	O

However	O
,	O
110	O
μM	O
Bromocriptine	B:C0006230
was	O
required	O
to	O
produce	O
a	O
similar	O
effect	O
in	O
GH3	O
cells	I:C0229535
.	O

However	O
,	O
110	O
μM	O
Bromocriptine	O
was	O
required	O
to	O
produce	O
a	O
similar	O
effect	O
in	O
GH3	B:C0229535
cells	I:C0229535
.	O

The	O
cell	B:C0007586
cycle	I:C0007586
was	O
arrested	O
at	O
the	O
G0	O
-	O
G1	O
phase	I:C1155840
and	O
S	O
phase	I:C1155869
.	O

The	O
cell	O
cycle	I:C0007586
was	O
arrested	B:C1155873
at	O
the	O
G0	O
-	O
G1	O
phase	I:C1155840
and	O
S	O
phase	I:C1155869
.	O

The	O
cell	O
cycle	I:C0007586
was	O
arrested	O
at	O
the	O
G0	B:C0079394
-	O
G1	O
phase	I:C1155840
and	O
S	O
phase	I:C1155869
.	O

The	O
cell	O
cycle	I:C0007586
was	O
arrested	O
at	O
the	O
G0	O
-	O
G1	B:C1155840
phase	I:C1155840
and	O
S	O
phase	I:C1155869
.	O

The	O
cell	O
cycle	I:C0007586
was	O
arrested	O
at	O
the	O
G0	O
-	O
G1	O
phase	I:C1155840
and	O
S	B:C1155869
phase	I:C1155869
.	O

As	O
the	O
concentration	O
and	O
time	O
increased	O
,	O
the	O
conversion	O
ratio	O
of	O
LC3	B:C2003747
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
increased	O
and	O
prolactin	O
secretion	I:C2611224
decreased	O
.	O

As	O
the	O
concentration	O
and	O
time	O
increased	O
,	O
the	O
conversion	O
ratio	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	B:C2003747
-	I:C2003747
II	I:C2003747
increased	O
and	O
prolactin	O
secretion	I:C2611224
decreased	O
.	O

As	O
the	O
concentration	O
and	O
time	O
increased	O
,	O
the	O
conversion	O
ratio	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
increased	O
and	O
prolactin	B:C2611224
secretion	I:C2611224
decreased	O
.	O

In	O
addition	O
,	O
Bcl	B:C0293686
-	I:C0293686
2	I:C0293686
and	O
BAX	O
expression	O
was	O
decreased	O
.	O

In	O
addition	O
,	O
Bcl	O
-	I:C0293686
2	I:C0293686
and	O
BAX	B:C0219474
expression	O
was	O
decreased	O
.	O

In	O
addition	O
,	O
Bcl	O
-	I:C0293686
2	I:C0293686
and	O
BAX	O
expression	B:C1171362
was	O
decreased	O
.	O

The	O
cell	B:C0007620
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	B:C0428411
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	B:C0229535
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	B:C0332293
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	B:C0072980
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	B:C0006230
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	B:C0229535
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	B:C0332293
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	O
.	O

The	O
cell	O
viability	I:C0007620
,	O
prolactin	O
level	I:C0428411
,	O
and	O
G0	O
-	O
G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
and	O
MMQ	O
cells	I:C0229535
treated	O
with	I:C0332293
a	O
high	O
concentration	O
of	O
Bromocriptine	B:C0006230
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	B:C0006230
,	O
treatment	O
with	O
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	O
,	O
treatment	B:C0087111
with	O
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	O
,	O
treatment	O
with	O
rapamycin	B:C0072980
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	O
,	O
treatment	O
with	O
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	B:C0006230
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	O
,	O
treatment	O
with	O
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	B:C2003747
-	I:C2003747
I	I:C2003747
to	O
LC3	O
-	I:C2003747
II	I:C2003747
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
Bromocriptine	O
,	O
treatment	O
with	O
rapamycin	O
and	O
a	O
low	O
concentration	O
of	O
Bromocriptine	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3	O
-	I:C2003747
I	I:C2003747
to	O
LC3	B:C2003747
-	I:C2003747
II	I:C2003747
.	O

Bromocriptine	B:C0006230
-	O
treated	O
pituitary	O
adenoma	I:C0032000
cells	O
mainly	O
underwent	O
autophagic	O
cell	O
death	I:C0007587
rather	O
than	O
apoptosis	O
.	O

Bromocriptine	O
-	O
treated	O
pituitary	B:C0032000
adenoma	I:C0032000
cells	O
mainly	O
underwent	O
autophagic	O
cell	O
death	I:C0007587
rather	O
than	O
apoptosis	O
.	O

Bromocriptine	O
-	O
treated	O
pituitary	O
adenoma	I:C0032000
cells	B:C0334227
mainly	O
underwent	O
autophagic	O
cell	O
death	I:C0007587
rather	O
than	O
apoptosis	O
.	O

Bromocriptine	O
-	O
treated	O
pituitary	O
adenoma	I:C0032000
cells	O
mainly	O
underwent	O
autophagic	B:C0004391
cell	O
death	I:C0007587
rather	O
than	O
apoptosis	O
.	O

Bromocriptine	O
-	O
treated	O
pituitary	O
adenoma	I:C0032000
cells	O
mainly	O
underwent	O
autophagic	O
cell	B:C0007587
death	I:C0007587
rather	O
than	O
apoptosis	O
.	O

Bromocriptine	O
-	O
treated	O
pituitary	O
adenoma	I:C0032000
cells	O
mainly	O
underwent	O
autophagic	O
cell	O
death	I:C0007587
rather	O
than	O
apoptosis	B:C0162638
.	O

